Alamar Biosciences to Present at Morgan Stanley Healthcare Conference

FREMONT, Calif., Sept. 01, 2026 /CourierPR/ -- Alamar Biosciences, a leader in precision proteomics, will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The company's management team will participate in a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time.

During the event, Alamar Biosciences' executives will discuss the company's advancements in protein detection and analysis. Interested attendees can access a live and archived webcast of the session on the company’s website at the "Investors" section, available at investors.alamarbio.com.

Alamar Biosciences, a commercial-stage proteomics company, has developed a platform called NULISA™ and the ARGO™ HT System. This technology enables the detection of protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, and seamless automation. According to the company, its Precision Proteomics platform fills a critical gap in advanced proteomics, aiding researchers in identifying a wide range of protein biomarkers across various disease states.

The company's approach to precision proteomics is distinct from traditional methods, offering flexibility and broad dynamic range. This technology is designed to revolutionize the early detection of diseases, a key focus for the company. Attendees of the Morgan Stanley conference can expect to gain insights into how Alamar Biosciences is leveraging its proprietary technology to advance the field of disease detection and analysis.